Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 511-521

  Fedele, Carmine ^a   Riccio, Gennaro ^a   Coppola, Carmela ^b   Barbieri, Antonio ^b   Monti, Maria Gaia ^a   Arra, Claudio ^b   Tocchetti, Carlo G ^b   D'Alessio, Giuseppe ^a   Maurea, Nicola ^b   De Lorenzo, Claudia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Cardiotoxicity; ErbB2 HER2; Herceptin Trastuzumab; Immunotherapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERBICIN DERIVED IMMUNOAGENT; ERBICIN RECOMBINANT RIBONUCLEASE; LAPATINIB; PERTUZUMAB; RIBONUCLEASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CELL SURVIVAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; DRUG SCREENING; EARLY DIAGNOSIS; FETUS; FRACTIONAL SHORTENING; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIAL STRAIN; TOXICITY TESTING; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; HEART; HUMANS; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES;

EID: 84863726300     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1783-9     Document Type: Article

References (29)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182
2. Stebbing J, Copson E, O'Reilly S (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26(4):287-290
3. Baselga J (2000) Current and planned clinical trials with trast-uzumab (Herceptin). Semin Oncol 27(5 Suppl 9):27-32
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Baja-monde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2. N Engl J Med 344(11):783-792
5. Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28(1 Suppl 3):20-27
6. Chien KR (2000) Myocyte survival pathways and cardiomyopa-thy: implications for trastuzumab cardiotoxicity. Semin Oncol 27(6 Suppl 11):9-14 discussion 92-100
7. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459-465. doi:10.1038/nm0502-459
8. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332-344. doi:10.1038/nrc2106
9. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23):5305-5313. doi:10.1200/JCO.2005.16. 584
10. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032-3038. doi:10.1200/JCO.2005.03.4744
11. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Men-delson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pert-uzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23(11):2534-2543. doi:10.1200/JCO.2005.03.184
12. Schneider JW, Chang AY, Rocco TP (2001) Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 28(5 Suppl 16):18-26
13. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G (2002) A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8(6):1710-1719
14. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R, D'Alessio G (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64(14):4870-4874
15. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Brit J Cancer 91(6):1200-1204. doi:10.1038/sj.bjc. 6602110
16. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26(11):1890-1895. doi: 10.1093/carcin/bgi146
17. Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C (2010) Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer 102(3):513-519. doi:10.1038/sj.bjc.6605499
18. De Lorenzo C, Troise F, Cafaro V, D'Alessio G (2007) Combinatorial experimental protocols for Erbicin-derived immuno-agents and Herceptin. Br J Cancer 97(10):1354-1360. doi:10. 1038/sj.bjc.6604022
19. Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C (2011) A novel ErbB2 epitope targeted by human antitumor immuno-agents. FEBS J 278(7):1156-1166. doi:10.1111/j.1742-4658. 2011.08041.x
20. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, De Lorenzo C (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 im-munoagents. FASEB J 23(9):3171-3178. doi:10.1096/fj.09-131383
21. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, Mitchell JB, Biswal S, Channon KM, Wolin MS, Alp NJ, Paolocci N, Champion HC, Kass DA (2008) Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydro-biopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117(20):2626-2636. doi:10.1161/CIRCULATIONAHA.107.737031
22. Peng Y, Popovic ZB, Sopko N, Drinko J, Zhang Z, Thomas JD, Penn MS (2009) Speckle tracking echocardiography in the assessment of mouse models of cardiac dysfunction. Am J Physiol 297(2):H811-H820. doi:10.1152/ajpheart.00385.2009
23. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di Gianni A, Serpico R, Iaccarino G, Sacca L (2003) Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 41(12):2154-2163. doi:10.1016/S0735-1097(03) 00483-2
24. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4(2):77-88. doi:10.1007/s11523-009-0112-2
25. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684
26. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83(6):679-686
27. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nole F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910-3916. doi:10.1200/JCO. 2009.27.3615
28. Ewer MS, Ewer SM (2010) Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol 28(25):3901-3904. doi:10.1200/JCO.2010.30.6274
29. Jassal DS, Han SY, Hans C, Sharma A, Fang T, Ahmadie R, Lytwyn M, Walker JR, Bhalla RS, Czarnecki A, Moussa T, Singal PK (2009) Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 22(4):418-424